AIM Vaccine (HKG:6660) is looking to raise net proceeds of HK$74.7 million from the placement of 15.5 million shares to Factorial Master Fund at HK$5.01 apiece, a Friday filing with the Hong Kong bourse said.
The shares represent 3.05% and 1.26% of its enlarged H share and issued share capital.
The drugmaker will use proceeds from the issue to accelerate the R&D of various pre-clinical and clinical programs; develop, market, and commercialize new products; and for working capital.
Shares of the company were down nearly 12% in recent trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.